Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older

Annals of Oncology

Volumn 10, Issue 4, 1999, Pages 397-402

  Vogel, C L ^a,g   O'Rourke, M ^b   Winer, E ^c   Hochster, H ^d   Chang, A ^e   Adamkiewicz, B ^f   White, R ^f   McGuirt, C ^f  

^a Compreh Cancer Research Group Inc ^*  (United States)

^b Greenville Office   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^e Genesee Hospital   (United States)

^f GLAXOSMITHKLINE   (United States)

^g Concorde Centre II ^*  (United States)

Author keywords

Breast cancer; Old age; Vinorelbine

Indexed keywords

NAVELBINE;

ADVANCED CANCER; AGING; ALOPECIA; ARTICLE; ASTHENIA; BREAST CARCINOMA; CLINICAL TRIAL; DOSE RESPONSE; DRUG SAFETY; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HUMAN; INJECTION PAIN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THORAX PAIN; VOMITING;

EID: 0032962603     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008364222793     Document Type: Article

References (25)

1. Yancik R, Ries LG. Cancer in the aged: An epidemiologic perspective on treatment issues. Cancer 1991 (Suppl); 68: 2493-510.
2. Yancik R, Ries LG, Yates JW. Breast cancer in aging women: A population-based study of contrasts in stage, surgery, and survival. Cancer 1989; 63: 976-81.
3. Busch E, Kemeny M, Fremgen A et al. Patterns of breast cancer care in the elderly. Cancer 1996; 78: 101-11.
4. Bruno S, Puerto VL, Mickiewicz E et al. Phase II trial of weekly i.v. vinorelbine as a single agent in first-line advanced breast cancer chemotherapy. The Latin-American experience. Am J Clin Oncol 1995; 18: 392-6.
5. Fumoleau P, Delgado FM, Delozier T et al. Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 1993; 11: 1245-52.
6. Garcia-Conde J, Lluch A, Martin M et al. Phase II trial of weekly i.v. vinorelbine in first-line advanced breast cancer chemotherapy. Ann Oncol 1994; 5: 854-7.
7. Romero A, Rabinovich MG, Vallejo CT et al. Vinorelbine as first-line chemotherapy for metastatic breast carcinoma. J Clin Oncol 1994; 12: 336-41.
8. Twelves CJ, Dobbs NA, Curnow A et al. A phase II multicentre, UK study of vinorelbine in advanced breast cancer. Br J Cancer 1994; 70: 990-3.
9. Vogel C, O'Rourke M, Weber B et al. The safety of i.v. Navelbine® in elderly patients with advanced breast cancer (ABC). Breast Cancer Res Treat 1994 (Suppl); 30: 36 (Abstr 31).
10. Weber BL, Vogel C, Jones S et al. Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer. J Clin Oncol 1995; 13: 2722-30.
11. Jones SJ, Winer E, Vogel C et al. Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. J Clin Oncol 1995; 13: 2567-74.
12. Vogel C, O'Rourke M, Winer E et al. A clinical trial of intravenous (i.v.) Navelbine (NVB) (vinorelbine tartrate) for first line treatment of women ≥ 60 years of age with advanced breast cancer (ABC). Proc Am Soc Clin Oncol 1996; 15: 101 (Abstr 70).
13. Sorio R, Robieux I, Galligioni E et al. Pharmacokinetics and tolerance of vinorelbine in elderly patients with metastatic breast cancer. Eur J Cancer 1997; 33: 301-3.
14. Buonadonna A, Crivellari D, Frustaci S et al. Vinorelbine (VRL) as palliative treatment in elderly patients with metastatic breast cancer. Breast Cancer Res Treat 1997; 46: 96 (Abstr 416).
15. Gladieff L, Houyau P, Mihura J et al. A phase II study with mitoxantrone-vinorelbine association in the treatment of advanced breast cancer in elderly women. Bull Cancer 1996; 83: 703-6.
16. Chevallier B, Mignot L, Delozier T et al. Phase II study of tetrahydropyranyl Adriamycin (pirarubicin) in elderly patients with advanced breast cancer. Am J Clin Oncol (CCT) 1992; 15: 395-8.
17. Repetto L, Simoni C, Venturino A et al. Mitoxantrone in elderly women with advanced breast cancer: A phase II study. Anticancer Res 1995; 15: 2297-300.
18. Taylor SG, Gelman RS, Falkson G et al. Combination chemotherapy compared to tamoxifen as initial therapy for stage IV breast cancer in elderly women. Ann Intern Med 1986; 104: 455-61.
19. Engelsman E, Klijn JCM, Rubens RD et al. 'Classical CMF' versus a three-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. Eur J Cancer 1991; 27: 966-70.
20. Gelman RS, Taylor SG. Cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer: The elimination of age trends in toxicity by using doses based on creatinine clearance. J Clin Oncol 1984; 2: 1404-13.
21. Hainsworth JD, Jolivet J, Hopkins E et al. A randomized phase II trial of mitoxantrone, 5-FU and high-dose leucovorin (NFL) versus cyclophosphamide, methotrexate, 5-FU (CMF) in the first-line treatment of metastatic breast cancer. Proc Am Soc Clin Oncol 1995; 14: 90 (Abstr 60).
22. Mammoliti S, Merlini L, Caroti C et al. Phase II study of mitoxantrone, 5-fluorouracil, and levo-leucovorin (MLF) in elderly advanced breast cancer patients. Breast Cancer Res Treat 1996; 37: 93-6.
23. Ibrahim NK, Frye DK, Buzdar AU et al. Doxorubicin-based chemotherapy in elderly patients with metastatic breast cancer. Arch Intern Med 1996; 156: 882-8.
24. Christman K, Muss HB, Case LD et al. Chemotherapy of metastatic breast cancer in the elderly: The Piedmont Oncology Association experience. JAMA 1992; 268: 57-62.
25. Rittenberg CN, Gralla RJ, Rehmeyer TA. Assessing and managing venous irritation associated with vinorelbine tartrate (Navelbine). Oncol Nurs Forum 1995; 22: 707-10.